Quantitative characterization of types 1 and 2 macular neovascularization in neovascular age-related macular degeneration with intravitreal conbercept: an analysis utilizing optical coherence tomography angiography. [PDF]
Int J OphthalmolShi YM +9 more
europepmc +2 more sources
Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy [PDF]
Drug Design, Development and Therapy, 2018 Yuting Peng, Xiongze Zhang, Miaoling Li, Bing Liu, Lan Mi, Chengguo Zuo, Feng Wen State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China Introduction: To evaluate the functional and morphological ...
Peng Y +6 more
doaj +3 more sources
Clinical efficacy of conbercept combined with micropulse laser in patients with polypoidal choroidal vasculopathy [PDF]
Lasers in Medical ScienceQingyan Liu +6 more
openalex +2 more sources
Subconjunctival conbercept for the treatment of corneal neovascularization
International Journal of Ophthalmology, 2023 AIM: To investigate the effectiveness and safety of subconjunctival injection of conbercept in the treatment of corneal neovascularization (CNV). METHODS: The data on 10 consecutively recruited patients with CNV who received a subconjunctival conbercept (1 mg) once, and measured the area, length, and diameter of neovascularization before and after (1d,
Cun Sun +3 more
openalex +5 more sources
VEGFA may be a potential marker of myopic choroidal thickness and vascular density changes [PDF]
Scientific ReportsTo evaluate the changes of choroidal thickness (CT) and blood flow related to myopia, and its effects of vascular endothelial growth factor (VEGFA) on choroidal vessels in myopia.
Ting Wan +5 more
doaj +2 more sources
Clinical efficacy and changes of serum VEGF-A, VEGF-B, and PLGF after conbercept treating neovascular age-related macular degeneration [PDF]
International Journal of Ophthalmology, 2023 AIM: To evaluate the clinical efficacy and systemic safety profile of conbercept in clinical practice on vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PLGF) levels after intravitreal injections for the neovascular age ...
Xiao-Dong Chen +5 more
doaj +1 more source
Review of Retinopathy of Prematurity Management in the Anti-VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI-Assisted Future. [PDF]
Clin Exp OphthalmolABSTRACT Retinopathy of prematurity (ROP) remains a major cause of preventable blindness in premature infants worldwide, with increasing incidence due to advancements in neonatal care. Management of ROP has been revolutionised by anti‐vascular endothelial growth factor (anti‐VEGF) treatments.
Marra KV +3 more
europepmc +2 more sources
Proteomic analysis of anti-angiogenic effects by conbercept in the mice with oxygen induced retinopathy [PDF]
International Journal of Ophthalmology, 2020 AIM: To analyze the retinal proteomes with and without conbercept treatments in mice with oxygen-induced retinopathy (OIR) and identify proteins involved in the molecular mechanisms mediated by conbercept.
Ji Jin +3 more
doaj +1 more source
Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis. [PDF]
Survey of ophthalmologyLaser photocoagulation (LPC) and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections constitute the current standard treatment for retinopathy of prematurity (ROP).
A. Ortiz-Seller +5 more
semanticscholar +3 more sources